Clopidogrel Viatris
Antiplatelet medication for preventing blood clots in atherosclerotic disease
Clopidogrel Viatris is a prescription antiplatelet medication containing 75 mg of clopidogrel. It works by preventing platelets from clumping together, thereby reducing the risk of dangerous blood clots in people with atherosclerotic cardiovascular disease. This comprehensive guide covers uses, correct dosage, potential side effects, drug interactions, and important safety information based on current European and international guidelines.
Quick Facts
Key Takeaways
- Clopidogrel Viatris is an antiplatelet drug that prevents blood clots by irreversibly blocking the P2Y12 receptor on platelets, reducing the risk of heart attack, stroke, and cardiovascular death.
- The standard maintenance dose is 75 mg once daily, taken at the same time each day with or without food. A loading dose of 300 mg or 600 mg may be given at the start of treatment.
- The most common side effect is bleeding; inform your doctor immediately if you experience unusual or prolonged bleeding, bruising, or signs of internal bleeding.
- Avoid omeprazole and esomeprazole while taking clopidogrel, as they can significantly reduce its effectiveness. Pantoprazole is a safer alternative if a proton pump inhibitor is needed.
- Never stop taking clopidogrel without consulting your doctor, as sudden discontinuation can significantly increase the risk of heart attack or stent thrombosis.
What Is Clopidogrel Viatris and What Is It Used For?
Clopidogrel Viatris contains the active substance clopidogrel and belongs to a class of medicines known as antiplatelet agents (specifically, P2Y12 receptor antagonists). Platelets are tiny blood cells that play a critical role in blood clotting. While clotting is essential for stopping bleeding from wounds, abnormal clot formation inside diseased arteries can block blood flow and lead to life-threatening events such as heart attacks and strokes.
Clopidogrel works by irreversibly binding to the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets. This prevents ADP from activating the GPIIb/IIIa complex, which is necessary for platelets to aggregate (clump together). Because the binding is irreversible, affected platelets remain inhibited for their entire lifespan of approximately 7 to 10 days. The body must produce new platelets to restore full clotting function after the drug is stopped.
Clopidogrel is a prodrug, meaning it must be converted into its active form by enzymes in the liver, primarily CYP2C19. This has important clinical implications, as genetic variations in CYP2C19 and certain drug interactions can affect how well clopidogrel works in an individual patient. Your doctor may consider these factors when prescribing this medication.
Approved Indications
Clopidogrel Viatris is prescribed for adults to prevent atherothrombotic events in the following clinical situations:
- Recent myocardial infarction (heart attack): To reduce the risk of further cardiovascular events in patients who have experienced a heart attack, typically as part of secondary prevention.
- Recent ischaemic stroke: To prevent recurrent strokes and other vascular events in patients who have had a stroke caused by a blood clot blocking an artery in the brain.
- Peripheral arterial disease (PAD): To reduce the risk of cardiovascular events in patients with established atherosclerosis affecting the blood vessels in the legs or other peripheral arteries.
- Acute coronary syndrome (ACS): In combination with aspirin (acetylsalicylic acid) for patients with unstable angina or myocardial infarction, including those who have undergone percutaneous coronary intervention (PCI) with stent placement.
- Transient ischaemic attack (TIA) or minor ischaemic stroke: In combination with aspirin for short-term dual antiplatelet therapy, typically for 21 days, followed by single antiplatelet therapy.
- Atrial fibrillation: In combination with aspirin for patients with atrial fibrillation who cannot take oral anticoagulants (vitamin K antagonists) and who are not at high risk of major bleeding. It should be noted that oral anticoagulants are generally more effective than the combination of clopidogrel and aspirin for stroke prevention in atrial fibrillation.
Clopidogrel has been used worldwide since its first approval in 1997 and is included on the WHO Model List of Essential Medicines. The CAPRIE, CURE, COMMIT, and CLARITY-TIMI 28 trials have established its efficacy in reducing atherothrombotic events across a range of cardiovascular conditions. It remains one of the most widely prescribed antiplatelet agents globally.
What Should You Know Before Taking Clopidogrel Viatris?
Clopidogrel Viatris is a potent antiplatelet medication, and there are several important considerations before you begin treatment. Your doctor will evaluate your individual risk factors and medical history to determine whether clopidogrel is appropriate for you. Open communication with your healthcare team is essential for safe and effective use of this medication.
Contraindications
You must not take Clopidogrel Viatris in the following circumstances:
- Hypersensitivity: If you are allergic to clopidogrel or any of the other ingredients in the tablet (listed in the composition section below).
- Active pathological bleeding: If you currently have an active bleed, such as a peptic ulcer or intracranial haemorrhage (bleeding in the brain).
- Severe hepatic impairment: If you have severe liver disease, as clopidogrel requires hepatic metabolism for activation and severe liver dysfunction can impair this process and increase bleeding risk.
Warnings and Precautions
Inform your doctor before taking Clopidogrel Viatris if any of the following apply to you:
- You have an increased risk of bleeding due to a medical condition that predisposes you to internal bleeding (e.g., a stomach ulcer), a blood disorder that makes you prone to bleeding into tissues, organs, or joints, or a recent serious injury.
- You have recently undergone surgery (including dental surgery) or have a surgical procedure planned within the next seven days. Clopidogrel is typically stopped 5-7 days before elective surgery.
- You have had an ischaemic stroke within the past seven days.
- You have kidney disease or liver disease of any severity.
- You have previously had a non-traumatic intracranial haemorrhage (brain bleeding not caused by external trauma).
- You have a history of allergic or haematological reactions to other thienopyridine antiplatelet agents (e.g., ticlopidine, prasugrel).
In rare cases, clopidogrel has been associated with a serious condition called Thrombotic Thrombocytopenic Purpura (TTP). Seek immediate medical attention if you develop fever, bruising under the skin appearing as small red pinpoint dots, unexplained severe fatigue, confusion, or yellowing of the skin or eyes (jaundice). TTP requires urgent medical treatment.
While taking clopidogrel, you should be aware that cuts and injuries may take longer than usual to stop bleeding. This is a normal consequence of how the medication works. For minor cuts (such as shaving nicks), this is generally not concerning. However, if you experience unusual or prolonged bleeding, contact your doctor immediately.
Pregnancy and Breastfeeding
Clopidogrel Viatris is not recommended during pregnancy. There are limited data on the use of clopidogrel in pregnant women, and animal studies have not shown direct or indirect harmful effects on reproductive function, but the potential risk to the human foetus is unknown. If you are pregnant, suspect you may be pregnant, or are planning to become pregnant, speak to your doctor before taking this medicine. If you become pregnant while taking clopidogrel, contact your doctor immediately.
Breastfeeding is not recommended while taking clopidogrel. Studies have shown that clopidogrel and its metabolites are excreted in breast milk in animal models. It is not known whether clopidogrel passes into human breast milk, and a risk to the breastfed infant cannot be excluded. Discuss alternative feeding options with your doctor if you need to take clopidogrel.
Use in Children
Clopidogrel Viatris is not indicated for use in children and adolescents under 18 years of age. There is insufficient evidence of efficacy in paediatric populations, and the safety profile has not been adequately established in this age group.
Driving and Operating Machinery
Clopidogrel Viatris is unlikely to affect your ability to drive or use machines. However, if you experience dizziness or other side effects that could impair your alertness, do not drive or operate machinery until these symptoms resolve.
Important Information About Excipients
Clopidogrel Viatris tablets contain lactose. If you have been told by your doctor that you have an intolerance to certain sugars, contact your doctor before taking this medicine. The tablets also contain sodium, but less than 1 mmol (23 mg) per tablet, meaning they are essentially sodium-free.
How Does Clopidogrel Viatris Interact with Other Drugs?
Drug interactions with clopidogrel can be broadly divided into two categories: those that increase the risk of bleeding and those that reduce the antiplatelet effectiveness of clopidogrel. Understanding these interactions is essential for safe treatment. Always tell your doctor or pharmacist about all medicines you are taking, including prescription drugs, over-the-counter medications, and herbal supplements.
Major Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Omeprazole / Esomeprazole | CYP2C19 inhibition; reduces active metabolite formation | Significantly reduces antiplatelet effect. Use pantoprazole or rabeprazole instead if PPI is needed. |
| Oral anticoagulants (warfarin, heparin) | Additive anticoagulant and antiplatelet effects | Substantially increased bleeding risk. Combination not generally recommended unless specifically indicated. |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Additive effects on bleeding; GI mucosal damage | Increased risk of gastrointestinal bleeding. Avoid concomitant use if possible; use with caution. |
| SSRIs (fluoxetine, fluvoxamine, etc.) | SSRIs affect platelet serotonin uptake; CYP2C19 inhibition | Increased bleeding risk and potential reduction in clopidogrel efficacy. Monitor closely. |
| Opioid analgesics | Delayed gastric emptying; slowed absorption | May delay and reduce clopidogrel absorption, potentially reducing its efficacy. Consider parenteral antiplatelet alternatives in acute settings. |
Other Notable Interactions
| Drug / Drug Class | Type of Interaction | Clinical Significance |
|---|---|---|
| Aspirin (acetylsalicylic acid) | Additive antiplatelet effect | Intentional combination in many indications (dual antiplatelet therapy). Increased bleeding risk; do not exceed prescribed aspirin dose. |
| Rifampicin | CYP enzyme induction; increases active metabolite | May increase clopidogrel's antiplatelet effect. Monitor for increased bleeding risk. |
| Fluconazole / Voriconazole | CYP2C19 inhibition | May reduce clopidogrel efficacy. Consider alternative antifungal agents if possible. |
| Carbamazepine | CYP enzyme induction | May alter clopidogrel metabolism. Clinical significance uncertain; monitor antiplatelet effect. |
| Repaglinide | CYP2C8 inhibition by clopidogrel metabolites | Clopidogrel can increase repaglinide exposure, raising hypoglycaemia risk. Monitor blood glucose closely. |
| Rosuvastatin | Increased rosuvastatin plasma levels | Clopidogrel may increase rosuvastatin exposure. Monitor for statin side effects (myalgia, rhabdomyolysis). |
| Paclitaxel | CYP2C8 inhibition | May increase paclitaxel exposure. Monitor for paclitaxel toxicity. |
When prescribed by your doctor, clopidogrel is commonly used in combination with low-dose aspirin (dual antiplatelet therapy, or DAPT). This is standard practice after acute coronary syndrome or coronary stent placement. However, occasional use of aspirin (no more than 1,000 mg in 24 hours) for pain relief is generally not considered problematic. Long-term aspirin use for other indications should be discussed with your doctor.
What Is the Correct Dosage of Clopidogrel Viatris?
Always take Clopidogrel Viatris exactly as your doctor or pharmacist has instructed. The tablets should be swallowed whole with water, at approximately the same time each day, with or without food. Consistent daily dosing is important to maintain steady antiplatelet protection.
Adults
Standard Maintenance Dose
The recommended maintenance dose for all approved indications is 75 mg of Clopidogrel Viatris once daily. This applies to patients with recent myocardial infarction, recent ischaemic stroke, established peripheral arterial disease, and atrial fibrillation (when combined with aspirin and oral anticoagulants are not suitable).
Acute Coronary Syndrome (Unstable Angina / NSTEMI / STEMI)
Treatment is typically initiated with a single loading dose of 300 mg (4 tablets of 75 mg). In patients undergoing percutaneous coronary intervention (PCI), a loading dose of 600 mg (8 tablets of 75 mg) may be given for faster onset of antiplatelet effect. After the loading dose, the standard maintenance dose of 75 mg once daily is continued, usually in combination with aspirin (75-100 mg daily). The duration of dual antiplatelet therapy is typically 6-12 months following stent placement, as determined by your cardiologist.
TIA or Minor Ischaemic Stroke
Treatment may be initiated with a single loading dose of 300 mg (4 tablets of 75 mg), followed by 75 mg once daily in combination with aspirin for 21 days. After this period, your doctor may continue treatment with either clopidogrel alone or aspirin alone.
Children and Adolescents
Clopidogrel Viatris is not recommended for use in patients under 18 years of age due to insufficient evidence of efficacy in this population.
Elderly Patients
No dose adjustment is required for elderly patients. However, elderly individuals are generally at higher risk of bleeding complications and may be more susceptible to side effects. Your doctor will carefully weigh the benefits of antiplatelet therapy against the bleeding risk in your individual case.
Renal and Hepatic Impairment
No dose adjustment is typically required for patients with mild to moderate kidney disease. Limited experience exists in patients with severe renal impairment, and clopidogrel should be used with caution in this group. Clopidogrel is contraindicated in severe liver disease. In patients with mild to moderate hepatic impairment, there may be reduced formation of the active metabolite, and the antiplatelet effect may be less pronounced. Your doctor will assess whether clopidogrel is appropriate for your level of liver function.
Missed Dose
If you forget to take a dose of Clopidogrel Viatris:
- If you remember within 12 hours of the missed dose, take the tablet immediately and then take your next dose at the usual time.
- If more than 12 hours have passed, simply skip the missed dose and take your next dose at the usual scheduled time.
- Do not take a double dose to compensate for a missed tablet.
Overdose
If you take more Clopidogrel Viatris than prescribed, or if someone accidentally ingests the medication, contact your doctor or the nearest hospital emergency department immediately. Overdose with clopidogrel may lead to an increased risk of bleeding and prolonged bleeding time. There is no specific antidote for clopidogrel. Platelet transfusion may be considered if rapid reversal of antiplatelet effect is clinically necessary.
Do not stop taking Clopidogrel Viatris unless your doctor tells you to. Abrupt discontinuation of clopidogrel, particularly within the first 12 months after coronary stent placement, can dramatically increase the risk of stent thrombosis, which is a medical emergency that can cause a massive heart attack. If you need to stop clopidogrel for any reason (e.g., surgery), consult your doctor first.
What Are the Side Effects of Clopidogrel Viatris?
Like all medicines, Clopidogrel Viatris can cause side effects, although not everyone experiences them. Because clopidogrel prevents platelets from clumping together, bleeding is the most frequently reported side effect. It is important to be aware of both common and serious side effects so that you can seek medical attention when needed.
Contact your doctor immediately if you experience: fever with signs of infection or severe fatigue (may indicate reduced blood cells); yellowing of the skin or eyes (jaundice) with or without tiny red pinpoint spots under the skin and confusion (may indicate TTP or liver problems); swelling of the mouth, skin rash, blisters, or severe itching (may indicate an allergic reaction); black tarry stools or vomiting blood (may indicate gastrointestinal bleeding).
Side Effects by Frequency
Common
- Bleeding (gastrointestinal, bruising, haematoma, nosebleed, blood in urine)
- Diarrhoea
- Abdominal pain
- Indigestion (dyspepsia)
- Heartburn
Uncommon
- Headache
- Stomach ulcer
- Nausea and vomiting
- Constipation
- Excessive gas (flatulence)
- Skin rash and itching
- Dizziness
- Tingling and numbness (paraesthesia)
Rare
- Vertigo
- Gynaecomastia (breast enlargement in males)
Very Rare
- Jaundice (yellowing of skin or eyes)
- Severe abdominal pain with or without back pain
- Fever and difficulty breathing, sometimes with cough
- Generalised allergic reactions (e.g., feeling of warmth with sudden general discomfort leading to fainting)
- Swelling of the mouth (angioedema)
- Blistering of the skin
- Skin allergic reactions (e.g., lichen planus-like eruptions)
- Mouth inflammation (stomatitis)
- Decreased blood pressure
- Confusion and hallucinations
- Joint pain (arthralgia) and muscle pain (myalgia)
- Changes in taste or loss of taste
Additionally, your doctor may detect changes in blood or urine tests while you are taking clopidogrel. A low platelet count (thrombocytopenia) and changes in white blood cell counts have been reported. In very rare cases, severe reductions in blood cell counts (agranulocytosis, pancytopenia, aplastic anaemia) have occurred.
Hypersensitivity reactions with chest or abdominal pain, as well as persistent symptoms of low blood sugar, have also been reported in post-marketing surveillance, though their exact frequency is unknown.
If you experience any side effects, including those not listed here, talk to your doctor or pharmacist. You can also report side effects directly to your national medicines regulatory authority (e.g., EMA in Europe, FDA in the United States, MHRA in the United Kingdom). By reporting side effects, you help provide important safety information about medicines.
How Should You Store Clopidogrel Viatris?
Proper storage of your medication is essential to ensure its effectiveness and safety. Follow these guidelines for storing Clopidogrel Viatris:
- Temperature: Store at or below 25°C (77°F). Do not freeze.
- Keep out of reach and sight of children.
- Expiry date: Do not use Clopidogrel Viatris after the expiry date (EXP) printed on the carton and blister pack. The expiry date refers to the last day of that month.
- Inspect before use: Do not use this medicine if you notice any visible signs of deterioration, such as discolouration or damage to the tablets or packaging.
- Disposal: Do not throw medicines away via wastewater or household waste. Return unused or expired medicines to your pharmacy for safe disposal. This helps protect the environment.
What Does Clopidogrel Viatris Contain?
Understanding the composition of your medication can be important, particularly if you have allergies or intolerances to specific ingredients. Below is the complete list of ingredients in Clopidogrel Viatris 75 mg film-coated tablets.
Active Substance
Each film-coated tablet contains 75 mg of clopidogrel (as clopidogrel besilate).
Inactive Ingredients (Excipients)
Tablet core: Hydroxypropylcellulose (E463), mannitol (E421), crospovidone (type A), citric acid monohydrate, microcrystalline cellulose, macrogol 6000, stearic acid, sodium stearyl fumarate.
Film coating: Lactose monohydrate, hypromellose (E464), triacetin (E1518), iron oxide red (E172), titanium dioxide (E171).
Appearance and Packaging
Clopidogrel Viatris 75 mg film-coated tablets are round, pink, and biconvex. They are supplied in PVC/PE/PVDC/aluminium blister packs in cartons containing 7, 14, 28, 30, 50, 56, 84, 90, or 100 film-coated tablets. Unit-dose blisters are available in pack sizes of 30 and 50 tablets. Not all pack sizes may be marketed in every country.
Frequently Asked Questions About Clopidogrel Viatris
Clopidogrel Viatris is an antiplatelet medication used to prevent blood clots (thrombosis) in adults with atherosclerotic cardiovascular disease. It is prescribed for patients who have had a heart attack, ischaemic stroke, or have peripheral arterial disease. It is also used in combination with aspirin for acute coronary syndrome (including after coronary stent placement), transient ischaemic attack (TIA) or minor stroke, and for selected patients with atrial fibrillation who cannot take oral anticoagulants.
The most common side effect is bleeding, which can include bruising, nosebleeds, gastrointestinal bleeding, and blood in the urine. Common non-bleeding side effects include diarrhoea, abdominal pain, indigestion, and heartburn. Cuts and injuries may take longer than usual to stop bleeding. Contact your doctor if you experience any unusual or prolonged bleeding.
This combination should be avoided. Omeprazole and esomeprazole inhibit the CYP2C19 enzyme, which is essential for converting clopidogrel into its active metabolite. Clinical studies have shown that omeprazole can reduce the antiplatelet effect of clopidogrel by approximately 45%. If you need a proton pump inhibitor while taking clopidogrel, your doctor will likely recommend pantoprazole or rabeprazole, which have less impact on CYP2C19.
The duration depends on your specific condition. After coronary stent placement, dual antiplatelet therapy (clopidogrel plus aspirin) is typically continued for 6-12 months. For secondary prevention after stroke or in peripheral arterial disease, long-term treatment may be recommended. After a TIA or minor stroke, short-term dual therapy (21 days) followed by monotherapy may be used. Your doctor will determine the optimal duration for your situation. Never stop clopidogrel without medical advice.
Clopidogrel is typically discontinued 5-7 days before elective surgery to allow sufficient time for new platelets to be produced and normal clotting function to return. However, stopping clopidogrel carries a risk of thrombotic events, particularly in patients with recent coronary stents. This decision must always be made by your doctor, who will weigh the surgical bleeding risk against the risk of cardiovascular events. For dental procedures, your dentist should be informed that you are taking clopidogrel.
If you remember within 12 hours, take the missed dose immediately and then continue with your normal schedule. If more than 12 hours have passed since the missed dose, skip it and take the next dose at the usual time. Do not take a double dose. To avoid missing doses, try taking clopidogrel at the same time every day, ideally linked to a daily routine such as a meal or brushing your teeth.
References
This article is based on the following peer-reviewed sources and authoritative medical guidelines:
- European Medicines Agency (EMA). Clopidogrel – Summary of Product Characteristics (SmPC). Available at: www.ema.europa.eu.
- Byrne RA, Rossello X, Coughlan JJ, et al. 2023 ESC Guidelines for the management of acute coronary syndromes. European Heart Journal. 2023;44(38):3720-3826. doi:10.1093/eurheartj/ehad191.
- Levine GN, Bates ER, Bittl JA, et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy. Journal of the American College of Cardiology. 2016;68(10):1082-1115.
- CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). The Lancet. 1996;348(9038):1329-1339.
- Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation (CURE trial). New England Journal of Medicine. 2001;345(7):494-502.
- Gilard M, Arnaud B, Cornily JC, et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. Journal of the American College of Cardiology. 2008;51(3):256-260.
- World Health Organization. WHO Model List of Essential Medicines – 23rd List (2023). Geneva: WHO; 2023.
- Joint Formulary Committee. British National Formulary (BNF). London: BMJ Group and Pharmaceutical Press. Clopidogrel monograph.
- Johnston SC, Easton JD, Farrant M, et al. Clopidogrel and Aspirin in Acute Ischemic Stroke and High-Risk TIA (CHANCE trial). New England Journal of Medicine. 2018;379(3):215-225.
- Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. The Lancet. 2001;358(9281):527-533.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, comprising licensed physicians with specialist training in cardiology, haematology, and clinical pharmacology.
iMedic Medical Editorial Team – Specialists in cardiovascular medicine and clinical pharmacology with extensive experience in evidence-based medical communication.
iMedic Medical Review Board – Independent panel of board-certified physicians who review all content against current ESC, AHA/ACC, and WHO guidelines using the GRADE evidence framework.
Editorial Standards: All content follows the iMedic editorial policy of evidence-based, peer-reviewed medical information with no commercial funding or pharmaceutical sponsorship. Evidence level: 1A (systematic reviews and meta-analyses of randomised controlled trials). For more information, see our editorial standards.